CMR Surgical Ltd, a Cambridge, UK-based company developing a next-generation surgical robot, closed a $100m Series B funding round.
Backers included new investor Zhejiang Silk Road Fund and existing investors Escala Capital Investments, LGT, Cambridge Innovation Capital and Watrium.
The company will use the proceeds to prepare its Versius® system for planned commercialisation. Activities will include the completion of validation studies for regulatory approval processes in both Europe and the USA, international expansion, and commercial scale-up.
Led by Martin Frost, Chief Executive Officer, CMR Surgical is developing a universal robotic system, Versius®, for minimal access surgery intended to be used across a range of surgical specialties. The company is conducting preclinical trials, demonstrating the ability of its Versius system to perform upper gastrointestinal, gynaecological, colorectal and renal surgery.